The global glioblastoma multiforme treatment market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.1 Billion by 2033, exhibiting a growth rate (CAGR) of 6.39% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 2.3 Billion |
Market Forecast in 2033
|
USD 4.1 Billion |
Market Growth Rate (2025-2033) | 6.39% |
Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation.
Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global glioblastoma multiforme treatment market report, along with forecasts at the global and regional level from 2025-2033. Our report has categorized the market based on drug type, route of administration, type of molecule, and distribution channel.
Breakup by Drug Type:
Breakup by Route of Administration:
Breakup by Type of Molecule:
Breakup by Distribution Channel:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals.
IMARC Group’s latest report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Drug Type, Route of Administration, Type of Molecule, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Companies Covered | Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global glioblastoma multiforme treatment market was valued at USD 2.3 Billion in 2024.
We expect the global glioblastoma multiforme treatment market to exhibit a CAGR of 6.39% during 2025-2033
The rising prevalence of oncological diseases, along with the growing consumer awareness towards the availability of numerous therapies for glioblastoma multiforme treatment, is primarily driving the global glioblastoma multiforme treatment market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of various elective glioblastoma multiforme treatment procedures across several nations to reduce the risk of the coronavirus infection upon hospital visits or interaction with healthcare professionals and medical equipment.
Based on the route of administration, the global glioblastoma multiforme treatment market can be categorized into oral and parenteral. Currently, oral accounts for the majority of the global market share.
Based on the type of molecule, the global glioblastoma multiforme treatment market has been segregated into small molecule and biologics, where small molecule currently exhibits a clear dominance in the market.
Based on the distribution channel, the global glioblastoma multiforme treatment market can be bifurcated into hospitals, pharmacies, and others. Currently, hospitals hold the largest market share.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global glioblastoma multiforme treatment market include Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem, and Arbor Pharmaceuticals.